Evidence map›Paper›PMID 39527321›Full record

ReviewMolecular biology reports2024

Evaluation of ploidy and the DNA index by flow cytometry in central nervous system tumors: a review.

Fernandez-Sanchez David, Ramirez-Corona Juan Antonio, Perez-Becerra Jose de Jesus, Santana-Bejarano Uriel Francisco, Santana-Hernandez Jennifer, Corona-Rivera Alfredo, Rodriguez-Machuca Victor Ulises, Bobadilla-Morales Lucina

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fernandez-Sanchez DavidHuman Genetics Institute "Dr. Enrique Corona-Rivera", Molecular Biology and Genomics Department, University Center of Health Sciences/Ph.D. Human Genetics Program, University of Guadalajara, Sierra Mojada #950, Independencia Oriente, Guadalajara, Jalisco, C.P. 44340, México.
Ramirez-Corona Juan AntonioHuman Genetics Institute "Dr. Enrique Corona-Rivera", Molecular Biology and Genomics Department, University Center of Health Sciences/Ph.D. Human Genetics Program, University of Guadalajara, Sierra Mojada #950, Independencia Oriente, Guadalajara, Jalisco, C.P. 44340, México.
Perez-Becerra Jose de JesusHuman Genetics Institute "Dr. Enrique Corona-Rivera", Molecular Biology and Genomics Department, University Center of Health Sciences/Ph.D. Human Genetics Program, University of Guadalajara, Sierra Mojada #950, Independencia Oriente, Guadalajara, Jalisco, C.P. 44340, México.
Santana-Bejarano Uriel FranciscoHuman Genetics Institute "Dr. Enrique Corona-Rivera", Molecular Biology and Genomics Department, University Center of Health Sciences/Ph.D. Human Genetics Program, University of Guadalajara, Sierra Mojada #950, Independencia Oriente, Guadalajara, Jalisco, C.P. 44340, México.
Santana-Hernandez JenniferHuman Genetics Institute "Dr. Enrique Corona-Rivera", Molecular Biology and Genomics Department, University Center of Health Sciences/Ph.D. Human Genetics Program, University of Guadalajara, Sierra Mojada #950, Independencia Oriente, Guadalajara, Jalisco, C.P. 44340, México.
Corona-Rivera AlfredoHuman Genetics Institute "Dr. Enrique Corona-Rivera", Molecular Biology and Genomics Department, University Center of Health Sciences/Ph.D. Human Genetics Program, University of Guadalajara, Sierra Mojada #950, Independencia Oriente, Guadalajara, Jalisco, C.P. 44340, México.
Rodriguez-Machuca Victor UlisesHuman Genetics Institute "Dr. Enrique Corona-Rivera", Molecular Biology and Genomics Department, University Center of Health Sciences/Ph.D. Human Genetics Program, University of Guadalajara, Sierra Mojada #950, Independencia Oriente, Guadalajara, Jalisco, C.P. 44340, México.
Bobadilla-Morales LucinaHuman Genetics Institute "Dr. Enrique Corona-Rivera", Molecular Biology and Genomics Department, University Center of Health Sciences/Ph.D. Human Genetics Program, University of Guadalajara, Sierra Mojada #950, Independencia Oriente, Guadalajara, Jalisco, C.P. 44340, México. lucinabo@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Research on central nervous system tumors (CNSTs) has a significant impact on the diagnosis and prognosis of patients. Currently, CNSTs are classified according to the schema proposed by the World Health Organization (WHO), which considers clinical, histopathological, and molecular characteristics, highlighting the importance of tumor biology for accurate diagnosis and optimal treatment approaches. Despite these advances, assessing DNA ploidy-a marker of tumor aggressiveness-remains complex in CNSTs. This review investigates the utility of DNA index (DNAi) and DNA ploidy analysis by flow cytometry in diagnosing CNSTs and prognosing their outcomes. We systematically reviewed studies in the PubMed database from 1990 to the present using the keywords "DNA Index", "Brain", "Flow cytometry", and "Ploidy". We identified 151 studies, 36 of which met our inclusion criteria. We found considerable variation in sample sizes and methodological variation across the studies. Discrepancies between the reported DNAi and ploidy values were observed. Aneuploidy is generally associated with more aggressive tumors, although exceptions exist. Higher DNAi levels correlate with increased malignancy, notably in glioblastomas, astrocytomas, and meningiomas, whereas diploid astrocytomas and oligodendrogliomas are associated with shorter survival rates. DNA ploidy assessment via flow cytometry could predict CNST behavior, yet methodological issues with tissue selection, adequate control samples, and technique variability remain. DNAi and ploidy assessments show promise as prognostic markers in CNSTs. However, the standardization of flow cytometry protocols and alignment with the current WHO classification schema are essential steps to integrate ploidy analysis in routine CNST assessment.

Indexed as

Central Nervous System NeoplasmsFlow CytometryPloidiesAneuploidyBiomarkers, TumorDNA, NeoplasmHumansPrognosisBiomarkers, TumorDNA, NeoplasmCNSTDNA indexFlow cytometryPloidy

Identifiers

PMID39527321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.